NBIX — Neurocrine Biosciences Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapNeutral

Annual balance sheet for Neurocrine Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	711	989	1,032	1,076	1,480
Net Total Accounts Receivable
Net Total Receivables	186	350	439	479	687
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	973	1,454	1,607	1,725	2,523
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	156	146	347	592	545
Net Intangible Assets
Long Term Investments
Other Long Term Assets
Total Assets	2,073	2,369	3,251	3,719	4,632
Payable / Accrued
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	246	538	655	508	743
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	699	661	1,019	1,129	1,378
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	1,374	1,708	2,232	2,590	3,253
Total Liabilities & Shareholders' Equity	2,073	2,369	3,251	3,719	4,632
Total Common Shares Outstanding